BUPIVACAINE INJECTION BP 2.5 MG — DIN 02443686
BUPIVACAINE HYDROCHLORIDE : 2.5 MG · STERIMAX INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is BUPIVACAINE INJECTION BP?
BUPIVACAINE INJECTION BP 2.5 MG contains BUPIVACAINE HYDROCHLORIDE : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02443686, held by STERIMAX INC, supplied as SOLUTION for EPIDURAL ; BLOCK/INFILTRATION administration. Health Canada currently lists it as marketed, status dated 20-May-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Bupivacaine cost around the world?
Bupivacaine is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Morocco publishes a PPV (public price); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 10 | 12 | SAR███.██ |
| United States | acquisition | 4 | 12 | USD███.██ |
| United Kingdom | hospital | 11 | 11 | GBP███.██ |
| Morocco | PPV (public price) | 7 | 7 | MAD███.██ |
| Czechia | max producer price (ex-factory) | 5 | 6 | CZK███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
53 pack listings across 42 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Bupivacaine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Bupivacaine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Bupivacaine, across 42 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| STERIMAX INC | 6 | 3 | BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP, BUPIVACAINE HYDROCHLORIDE INJECTION, USP, BUPIVACAINE INJECTION BP | Sourceable in Canada |
| PFIZER CANADA ULC | 6 | 2 | MARCAINE, MARCAINE SPINAL | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 2 | 2 | SENSORCAINE | Sourceable in Canada |
| BAXTER CORPORATION | 3 | 1 | BUPIVACAINE HYDROCHLORIDE INJECTION, USP | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 2 | 1 | BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP, BUPIVACAINE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| FORMATIVE PHARMA INC. | 1 | 1 | BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 5 | 0 | BUPIVACAINE HYDROCHLORIDE INJECTION USP | No marketed DIN |
| JAMP PHARMA CORPORATION | 4 | 0 | JAMP-BUPIVACAINE | No marketed DIN |
| SANOFI CANADA, INC. | 4 | 0 | MARCAINE 0.25% LIQ PRT 2.5MG/ML, MARCAINE 0.50% LIQ BIN 5MG/ML, MARCAINE 0.75% LIQ PRT 7.5MG/ML, MARCAINE 0.75% LIQ SPINAL 7.5MG/ML | No marketed DIN |
| AURO PHARMA INC | 3 | 0 | BUPIVACAINE HEAVY INJECTION BP, BUPIVACAINE INJECTION BP | No marketed DIN |
| EUGIA PHARMA INC. | 3 | 0 | BUPIVACAINE HEAVY INJECTION BP, BUPIVACAINE INJECTION BP | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 3 | 0 | BUPIVACAINE HYDROCHLORIDE INJECTION USP .25%, BUPIVACAINE HYDROCHLORIDE INJECTION USP .50%, BUPIVACAINE HYDROCHLORIDE INJECTION USP .75% | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | EPIDURAL ; BLOCK/INFILTRATION |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Bupivacaine |
|---|---|
| ATC code | N01BB01 |
| AHFS class | 72:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02443686 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2443686 |
| Brand name | BUPIVACAINE INJECTION BP |
| Generic / active ingredient | BUPIVACAINE HYDROCHLORIDE : 2.5 MG |
| Market authorization holder | STERIMAX INC |
| Health Canada schedule | Ethical |
| ATC code | N01BB01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N01BB |
| Current status | MARKETED |
| Status date | 20-May-2016 |
| Original market date | 2016-05-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Bupivacaine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 42 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02512424 |
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | STERIMAX INC | MARKETED | 02460645 |
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | FORMATIVE PHARMA INC. | MARKETED | 02536714 |
| BUPIVACAINE HYDROCHLORIDE INJECTION, USP | 7.5 MG | SOLUTION | BAXTER CORPORATION | MARKETED | 02488930 |
| BUPIVACAINE INJECTION BP | 5 MG | SOLUTION | STERIMAX INC | MARKETED | 02443694 |
| MARCAINE | 250 MG / 50 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02305909 |
| MARCAINE | 150 MG / 20 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02241917 |
| SENSORCAINE | 2.5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 01976141 |
| SENSORCAINE | 5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 01976168 |
| BUPIVACAINE HEAVY INJECTION BP | 15 MG / 2 ML | SOLUTION | AURO PHARMA INC | APPROVED | 02470616 |
2 · Same class — other molecules in ATC N01BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | AMNIOCENTESIS TRAY 1% · ANTECUBITAL CENT VENOUS CATHETERIZATION KIT · ARTHROGRAM TRAY 1% · ATELOCOLLAGEN IMPLANT · +39 more | 72 | 26 | Yes |
| Lidocaine, Combinations | 2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP · 5% XYLOCAINE MPF WITH GLUCOSE 7.5% INJECTION · ARROW CENTRAL VENOUS CATHETERIZATION KIT · ARROW MULTI-LUMEN CENTRAL VENOUS CATHETER KIT · +55 more | 72 | 16 | Yes |
| Articaine, Combinations | 4% ASTRACAINE DENTAL WITH EPINEPHRINE 1:200,000 (0.005MG/ML) · 4% ASTRACAINE DENTAL WITH EPINEPHRINE FORTE 1:100,000 (0.01MG/ML) · ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION · ORABLOC 1:100,000 · +10 more | 18 | 12 | Yes |
| Bupivacaine | BUPIVACAINE HEAVY INJECTION BP · BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP .25% · +12 more | 42 | 10 | Yes |
| Mepivacaine | 3% POLOCAINE DENTAL · CARBOCAINE 1% · CARBOCAINE 2% · CARBOCAINE 3% · +7 more | 15 | 7 | Yes |
| Ropivacaine | NAROPIN · NAROPIN INJ 7.5MG/ML · ROPIVACAINE HYDROCHLORIDE INJECTION · ROPIVACAINE HYDROCHLORIDE INJECTION USP · +2 more | 13 | 6 | Yes |
| Bupivacaine, Combinations | BUPIVACAINE HCL 0.5% AND EPINEPHRINE 1:200,000 INJECTION · MARCAINE · MARCAINE 0.5% AND EPINEPHRINE 1:200,000 LIQ · MARCAINE E · +5 more | 12 | 5 | Yes |
| Prilocaine, Combinations | 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 · DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 · EMLA CREAM · EMLA PATCH · +1 more | 5 | 4 | Yes |
| Combinations | CETACAINE LIQUID · ORAQIX | 2 | 2 | Yes |
| Prilocaine | 4% CITANEST PLAIN DENTAL · DENTSPLY 4% PRILOCAINE HYDROCHLORIDE DENTAL INJECTION | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N01BA | Benzocaine · Chloroprocaine · Combinations,Of Anesthetics · Procaine · Tetracaine | 13 | 1 |
| N01BX | Phenol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BUPIVACAINE INJECTION BP called?
The same molecule, Bupivacaine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| BUPIVACAINE NORIDEM | Latin | Czechia |
| Bucaine Spinal | Latin | Saudi Arabia |
| MARCAINE | Latin | Czechia |
| MARCAINE SPINAL | Latin | Czechia |
| MARCAINE SPINAL HEAVY | Latin | Czechia |
| Micro Bupivacaine | Latin | South Africa |
| SALVUDEX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.